Compare AGCO & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGCO | QGEN |
|---|---|---|
| Founded | 1990 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 10.2B |
| IPO Year | 1994 | 1998 |
| Metric | AGCO | QGEN |
|---|---|---|
| Price | $122.25 | $40.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $118.73 | $51.30 |
| AVG Volume (30 Days) | 584.3K | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | 0.95% | ★ 5.88% |
| EPS Growth | ★ 271.35 | N/A |
| EPS | ★ 9.75 | N/A |
| Revenue | ★ $10,082,000,000.00 | N/A |
| Revenue This Year | $6.55 | $8.18 |
| Revenue Next Year | $5.59 | $5.71 |
| P/E Ratio | ★ $12.54 | $24.01 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $78.37 | $38.80 |
| 52 Week High | $143.78 | $57.82 |
| Indicator | AGCO | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 42.69 |
| Support Level | $102.57 | $38.80 |
| Resistance Level | $143.78 | $48.96 |
| Average True Range (ATR) | 3.24 | 0.85 |
| MACD | 1.26 | 0.45 |
| Stochastic Oscillator | 91.02 | 67.50 |
Agco is a global manufacturer of agricultural equipment. Its main machine brands are Fendt, Massey Ferguson, and Valtra; its initiatives in precision agriculture have been organized under the PTx umbrella following a series of acquisitions. While a global business, Agco's sales skew heavily toward Europe/Middle East, representing 50%-60% of sales and even more of operating profits. The company is trying to increase its exposure to the larger North and South American markets. Its products are available through a global dealer network, which includes over 3,000 dealer and distribution locations and reach into over 140 countries. Additionally, Agco offers retail and wholesale financing to customers through its unconsolidated joint venture with Rabobank of the Netherlands.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).